Neurometrix Stock Today
| NURO Stock | USD 4.37 0.02 0.46% |
PerformanceSolid
| Odds Of DistressLow
|
NeuroMetrix is selling at 4.37 as of the 17th of March 2025; that is 0.46 percent increase since the beginning of the trading day. The stock's open price was 4.35. NeuroMetrix has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. The company has 2.05 M outstanding shares of which 1.4 K shares are now shorted by private and institutional investors with about 0.19 trading days to cover. More on NeuroMetrix
Moving together with NeuroMetrix Stock
Moving against NeuroMetrix Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
NeuroMetrix Stock Highlights
NeuroMetrix (NURO) is traded on NASDAQ Exchange in USA. It is located in 4B Gill Street, Woburn, MA, United States, 01801 and employs 26 people. NeuroMetrix is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.97 M. NeuroMetrix conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 2.05 M outstanding shares of which 1.4 K shares are now shorted by private and institutional investors with about 0.19 trading days to cover.
NeuroMetrix currently holds about 20.83 M in cash with (6.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68.
Check NeuroMetrix Probability Of Bankruptcy
Ownership AllocationNeuroMetrix secures 15.16 % of its outstanding shares held by insiders and 17.4 % owned by institutional investors.
Check NeuroMetrix Ownership Details
NeuroMetrix Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. NeuroMetrix market risk premium is the additional return an investor will receive from holding NeuroMetrix long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.2067 | |||
| Jensen Alpha | 0.2504 | |||
| Total Risk Alpha | 0.3696 | |||
| Sortino Ratio | 0.3863 |
NeuroMetrix Stock Against Markets
NeuroMetrix Corporate Executives
Elected by the shareholders, the NeuroMetrix's board of directors comprises two types of representatives: NeuroMetrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuroMetrix. The board's role is to monitor NeuroMetrix's management team and ensure that shareholders' interests are well served. NeuroMetrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuroMetrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Higgins | CFO, Principal Accounting Officer, Sr. VP and Treasurer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeuroMetrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in NeuroMetrix Stock, please use our How to Invest in NeuroMetrix guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuroMetrix. If investors know NeuroMetrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuroMetrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NeuroMetrix is measured differently than its book value, which is the value of NeuroMetrix that is recorded on the company's balance sheet. Investors also form their own opinion of NeuroMetrix's value that differs from its market value or its book value, called intrinsic value, which is NeuroMetrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuroMetrix's market value can be influenced by many factors that don't directly affect NeuroMetrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuroMetrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuroMetrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuroMetrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.